Home
Scientific R&D
Research Ability
Pipeline
News Activity
News Center
News
Createrna was invited to participate in the Chinese Pharmaceutical Innovation Investment Forum
MY004567 tablets was clinically approved by FDS
The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
Dr. Jing Zhang, formerly Head of the Clinical Team at the FDA's Center for Drug Approval, serves as CMO of Createrna
MY004567 tablets was approved by the FDA US. for clinical trials implied
Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
Createrna Receives Capital Injection from Well-known Investment Institutions
About Us
About Createrna
Company Introduction
Development course
Management Team
Honor and Qualification
Partner
Our Culture
Contact Us
Join Us
Careers
Recruitment